Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro Data.

Clinical pharmacology and therapeutics - 1 Aug 2025

Umehara Kenichi, Parrott Neil, Günther Andreas, Bogman Katrijn

Abstract excerpt

Vicasinabin is an oral cannabinoid receptor 2 (CB2) agonist showing anti-inflammatory effects and was developed for the treatment of chronic inflammatory diseases such as diabetic retinopathy. Vicasinabin is mainly metabolized by CYP3A4, with minor contributions from CYP2C19 and UGTs. The drug shows in vitro induction of CYP3A4, as well as inhibition of hepatic and renal transporters. Translation of in vitro data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C19
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to CYP3A4 gene

Share to Genotype

Share to Midazolam

Share to Models, Biological

Share to Risk Assessment

Source

Identifiers

PMID: 40294080
DOI: 10.1002/cpt.3686

Genes

CYP3A4
CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro Data.PMID 40294080Read ↗

Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.Semantic proximity Read ↗

A Digital Twin of Glimepiride for Personalized and Stratified Diabetes TreatmentSemantic proximity Read ↗

Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.Semantic proximity Read ↗

Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.Semantic proximity Read ↗

Assessment of the CYP1A2 Inhibition-Mediated Drug Interaction Potential for Pinocembrin Using In Silico , In Vitro , and In Vivo ApproachesSemantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.Semantic proximity Read ↗

The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions.Semantic proximity Read ↗

A useful tool for drug interaction evaluation: The University of Washington Metabolism and Transport Drug Interaction DatabaseSemantic proximity Read ↗

Risk Assessment for Drug-Induced Hyperbilirubinemia: A Mechanistic Approach.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.Semantic proximity Read ↗

Medicinal Cannabis - Potential Drug InteractionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.